Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORP-AF General Long-Term Registry.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
revised:
06
08
2020
received:
27
02
2020
accepted:
02
09
2020
pubmed:
12
9
2020
medline:
12
5
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
This study aimed to (1) define the prevalence of vascular disease (VD; coronary (CAD) and/or peripheral artery disease (PAD)) and associated risk factors in patients with atrial fibrillation (AF); (2) establish the relationship of VD and associated treatment patterns on adverse events in AF. Data from 701 Polish AF patients enrolled in the EORP-AF General Long-Term Registry in the years 2013-2016 were included in this analysis. During the one-year follow-up, the occurrence of major adverse events (MAE; all-cause death, thromboembolic event, myocardial infraction) and its components was evaluated. VD was recorded in 293 (44%) patients and based on multivariate logistic analysis was associated with age >75, diabetes, hypercholesterolemia, heart failure (HF). There was no significant difference in rates of MAE between patients with and without VD based on Fisher's exact test (8.8% vs 5.7%, P = .16), as well as between patients with concomitant CAD and PAD, PAD and CAD alone based on the Chi-square test (21% vs 7.5% vs 6.7%; P = .09). A higher risk of MAE was associated with HF, chronic kidney disease (in all study group), age >75, HF, diabetes (VD group),chronic obstructive pulmonary disease (non-VD group) based on the multivariate logistic analysis. Relative to patients with VD on vitamin K antagonists (VKA), those treated with non-VKA-oral anticoagulants (NOAC) had lower absolute rate of MAE according to Fisher's exact test (1.4% vs 10%, P = .02) but similar risks for thromboembolic and hemorrhagic events. The concomitant use of triple therapy was associated with increased risk of MAE as compared with those on OAC alone or dual therapy based on the Chi-square test (20% vs 4.8%, 3.2%, P = .02). VD was prevalent in almost two-fifths of AF patients. The incidence of MAE was higher in patients with VD on VKA (vs NOAC) and on triple therapy (vs dual therapy, OAC alone) within one-year follow-up.
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13701Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Inohara T, Shrader P, Pieper K, et al. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: results from the outcomes registry for better informed treatment of atrial fibrillation II. Am Heart J. 2019;213:81-90.
Pastori D, Pignatelli P, Sciacqua A, Perticone M, Violi F, Lip GYH. Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. Int J Cardiol. 2018;255:69-73.
Pastori D, Farcomeni A, Poli D, et al. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Intern Emerg Med. 2016;11:199-204.
Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB, Lip GY. Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation: a focus on vascular disease, women, and simple practical application. Can J Cardiol. 2015;31(820):e9-e10.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154:1121-1201.
Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20:747-757.
Lodziński P, Gawałko M, Budnik M, et al. Trends in antithrombotic management of patients with atrial fibrillation. A report from the Polish part of the EURObservational Research Programme - Atrial Fibrillation General Long-Term Registry. Pol Arch Int Med. 2020.30:196-205.
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
Violi F, Lip GYH, Basili S. Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. Intern Emerg Med. 2012;7:213-218.
Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease - Double trouble. Adv Med Sci. 2018;63:30-35.
Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3:229-234.
Olesen JB, Gislason GH, Torp-Pedersen C, Lip GY. Atrial fibrillation and vascular disease-a bad combination. Clin Cardiol. 2012;35(Suppl 1):15-20.
Shahid F, Pastori D, Violi F, Lip GYH. Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. Pharmacol Res. 2018;132:149-159.
Anandasundaram B, Lane DA, Apostolakis S, Lip GYH. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. J Thromb Haemost. 2013;11:975-987.
Börschel CS, Schnabel RB. The imminent epidemic of atrial fibrillation and its concomitant diseases - myocardial infarction and heart failure - a cause for concern. Int J Cardiol. 2019;287:162-173.
Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988.
Chen ST, Hellkamp AS, Becker RC, et al. Impact of polyvascular disease on patients with atrial fibrillation: insights from ROCKET AF. Am Heart J. 2018;200:102-109.
Singer DE, Ezekowitz MD. Adding rigor to stroke risk prediction in atrial fibrillation. J Am Coll Cardiol. 2015;65:233-235.
Winkel TA, Hoeks SE, Schouten O, et al. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg. 2010;40:9-16.
Goto S, Bhatt DL, Röther J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855-863.
Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J. 2014;35:242-249.
Lin Y-S, Tung T-H, Wang J, et al. Peripheral arterial disease and atrial fibrillation and risk of stroke, heart failure hospitalization and cardiovascular death: a nationwide cohort study Int. J Cardiol. 2016;203:204-211.
Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: virchow’s triad revisited. Lancet. 2009;373:155-166.
Romero N, Lupi K, Carter D, Malloy R. The role of double and triple therapy with direct oral anticoagulants in coronary artery disease, peripheral artery disease, and stroke. Clin Ther. 2018;40(11):1907-1917.e3.
Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017. Pharmacotherapy. 2018;38:907-920.
Lamberts M, Gislason GH, Lip GYH, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2019;129:1577-1585.
Sindet-Pedersen C, Lamberts M, Staerk L, et al. Combining oral anticoagulants with platelet inhibitors in patients with atrial fibrillation and coronary disease. J Am Coll Cardiol. 2018;72:1790-1800.
Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423-2434.
Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513-1524.